CSV audit Archives

13/10/2026

Introduction

Data integrity is a fundamental requirement for maintaining GxP compliance in pharmaceutical, biotechnology, and life sciences organizations. As artificial intelligence (AI) becomes more common in regulated environments, companies must ensure that the data used to develop, train, validate, and operate AI systems remains accurate, complete, consistent, and traceable.

An AI system may process large amounts of information, identify patterns, support quality decisions, or assist with manufacturing and laboratory activities. However, unreliable data can affect the accuracy of its outputs and create potential compliance risks. Therefore, organizations need a structured approach to audit AI data integrity in a GxP environment.

An effective audit should examine both training data and operational data. It should also evaluate data governance, access controls, audit trails, model changes, data processing, and corrective actions.

GxP Cellators provides specialized AI auditing services to help pharmaceutical and life sciences organizations assess data integrity controls, identify compliance gaps, and strengthen their audit readiness.

Why Is AI Data Integrity Important in a GxP Environment?

GxP environments require organizations to maintain reliable records and follow documented procedures that support product quality, patient safety, and data reliability. When AI systems are introduced into these environments, the same principles must be considered throughout the data lifecycle.

For example, an AI application used to review laboratory results may produce unreliable recommendations if its training data contains incomplete or inaccurate records. Similarly, an AI system supporting pharmaceutical manufacturing may generate misleading outputs if operational data is modified without appropriate controls.

Poor AI data integrity can lead to several problems:

Inaccurate or inconsistent AI-generated outputs.
Incomplete or unreliable electronic records.
Unauthorized changes to data or model configurations.
Limited traceability of AI-generated recommendations.
Weak documentation and audit trail controls.
Difficulty investigating deviations and data integrity incidents.
Increased risk during regulatory inspections.

Consequently, organizations should evaluate AI data integrity as part of their broader GxP quality management and computerized system governance processes.

Step 1: Understand the AI System and Its Intended Use

Before beginning an audit, auditors should understand how the AI system operates and how it supports regulated activities. The intended use determines the type of data involved, the risks associated with the system, and the controls that need to be reviewed.

Start by documenting the following information:

What is the intended use of the AI system?
Which GxP processes does it support?
What data is used to train the model?
What operational data does the system receive?
How is the data processed, transferred, and stored?
Does the AI system influence product quality, laboratory results, or other regulated decisions?
Who is responsible for system oversight and data management?

Auditors should also review relevant system documentation, risk assessments, validation records, standard operating procedures (SOPs), and data flow diagrams.

Understanding the system first helps auditors identify critical data points and determine which controls require closer examination.

Step 2: Assess Training Data Integrity

Training data plays an important role in determining how an AI model learns and performs. If the data is incomplete, inaccurate, outdated, or unsuitable for its intended purpose, the model may produce unreliable results.

A training data audit should examine the origin, quality, suitability, and traceability of the datasets used to develop the AI system.

Verify Data Sources and Reliability

Auditors should establish where training data originated and whether the organization has documented its sources. Data collected from laboratory systems, manufacturing equipment, quality management systems, historical records, or external providers should have appropriate provenance documentation.

The audit should determine whether the organization can explain how the data was obtained and whether its use is appropriate for the intended application.

Review Completeness and Representativeness

Training datasets should be assessed for missing values, duplicate records, inconsistencies, and other quality issues. Auditors should also evaluate whether the dataset adequately represents the conditions under which the AI system is expected to operate.

Where relevant, the review should consider potential bias, unusual data patterns, and limitations that could affect model performance.

Examine Data Preprocessing

AI development may involve data cleaning, transformation, normalization, filtering, or annotation. These activities should be documented so that the organization can explain how the original data was changed before it was used for training.

Auditors should check whether preprocessing steps are reproducible, justified, and subject to appropriate review.

Confirm Data Provenance and Lineage

Data provenance identifies where data came from, while data lineage helps explain how it moved through different systems and processing stages.

An effective audit should verify that the organization maintains suitable records to trace datasets from their original sources through preparation, model training, and subsequent use.

Step 3: Assess Operational Data Integrity

Training data is only one part of the audit. Operational data must also remain reliable after an AI system is deployed.

Operational data may include user inputs, laboratory results, manufacturing information, model outputs, system logs, and records generated during routine use.

Review Audit Trails

Auditors should determine whether relevant system activities are recorded and whether the audit trails provide sufficient information to reconstruct important events.

Depending on the system, this may include data creation, modification, deletion, access, processing, and model-related changes.

The audit should also verify whether audit trails are protected against unauthorized alteration and reviewed according to documented procedures.

Evaluate Access Controls

Access controls help prevent unauthorized users from viewing, modifying, exporting, or deleting regulated data.

Auditors should review user roles, permissions, authentication controls, privileged access, and periodic access reviews. They should also determine whether access rights follow the principle of least privilege.

Shared accounts and excessive permissions may reduce accountability and make investigations more difficult.

Examine AI Outputs and Traceability

Organizations should be able to identify the relevant input data, system version, and processing context associated with important AI outputs.

Where appropriate, records should identify the user or system responsible for an action and document how the output was reviewed or used in a regulated decision.

Auditors should also determine whether human review is required for critical decisions and whether that review is documented.

Review Data Backup and Recovery

Data backups help protect information against accidental deletion, system failures, and other incidents. However, having a backup process alone is not sufficient.

Auditors should examine backup schedules, storage protections, recovery procedures, and evidence of restoration testing. They should also verify that recovered data remains complete and usable.

Step 4: Review Data Governance and ALCOA+ Principles

A documented data governance framework helps organizations define responsibilities and maintain control over data throughout its lifecycle.

Auditors should check whether responsibilities for data ownership, quality monitoring, access management, incident reporting, and record retention are clearly defined.

They should also review whether employees receive appropriate training and whether procedures explain how data integrity issues must be reported, investigated, and resolved.

Apply ALCOA+ Principles to AI Data

ALCOA+ is a widely used framework for evaluating data integrity in regulated environments. Its principles provide a useful basis for assessing the reliability of relevant AI records.

The audit should consider whether data is:

Attributable: The person or system responsible for an action can be identified.
Legible: Records remain readable and understandable throughout their retention period.
Contemporaneous: Data is recorded at the time the activity takes place.
Original: Original records or verified true copies are retained as required.
Accurate: Records correctly reflect the activity or observation.
Complete: Relevant data, metadata, and associated records are retained.
Consistent: Records follow the expected sequence and remain internally consistent.
Enduring: Data remains preserved throughout the required retention period.
Available: Records can be retrieved when needed for review or inspection.

For AI applications, auditors should consider how these principles apply to source datasets, preprocessing records, operational inputs, generated outputs, audit trails, and relevant metadata.

Step 5: Review Model Changes and Data Lifecycle Controls

AI systems may change over time as datasets are updated, models are retrained, software components are modified, or system configurations are adjusted.

These changes can affect system performance and may introduce new data integrity risks.

Auditors should review whether model and system changes are documented, assessed for risk, reviewed, tested, and approved before implementation where required.

The audit should also examine:

Version control for models and relevant datasets.
Records of model training and retraining.
Change control procedures.
Impact assessments for significant changes.
Testing and validation evidence.
Approval records and implementation history.
Monitoring for unexpected changes in system performance.

Organizations should define suitable controls based on the AI system’s intended use and its potential impact on GxP processes. Changes that may affect product quality, patient safety, or data reliability require particular attention.

Step 6: Identify Compliance Gaps and Develop a Remediation Plan

Once the audit is complete, the findings should be documented and assessed according to their potential impact.

Not every observation presents the same level of risk. Therefore, organizations should prioritize issues based on factors such as data criticality, potential impact on product quality, patient safety, regulatory compliance, and the reliability of decisions supported by the AI system.

A structured remediation process should include the following activities:

Document each finding with supporting evidence.
Assess the potential impact and associated risk.
Identify the underlying cause of significant issues.
Assign corrective and preventive actions (CAPA).
Define action owners, responsibilities, and target dates.
Implement approved corrective actions.
Verify that the actions have been completed effectively.
Maintain records and escalate unresolved high-risk issues.

For example, if an audit identifies incomplete documentation of training data preprocessing, the organization may need to update procedures, reconstruct available records, introduce review controls, and verify that the revised process is followed consistently.

A clear remediation plan helps turn audit observations into measurable improvements rather than leaving findings unresolved.

Common Challenges During AI Data Integrity Audits

Organizations may encounter several challenges when auditing AI systems in regulated environments.

Limited data traceability: Data may pass through several applications, databases, and processing tools, making it difficult to establish a complete history.

Insufficient documentation: Training data preparation, model changes, or operational decisions may not be documented consistently.

Unclear accountability: Responsibilities may be divided between IT teams, data scientists, quality assurance, and external technology providers.

Weak access management: Excessive permissions or shared accounts can reduce accountability and increase the risk of unauthorized changes.

Inadequate change control: Model updates may be introduced without a sufficient assessment of their impact on the intended GxP use.

Incomplete remediation: Organizations may close audit findings without verifying whether the underlying problem has been resolved.

Addressing these challenges requires cooperation between quality assurance, IT, data management, validation, and business teams.

How GxP Cellators Supports AI Data Integrity Audits

GxP Cellators provides specialized AI auditing services for pharmaceutical companies and other regulated life sciences organizations. Its approach focuses on reviewing data integrity controls, evaluating compliance risks, and identifying practical opportunities for improvement.

AI data integrity audit support may include:

Training data quality and provenance audits.
Operational data integrity assessments.
Data governance framework reviews.
Audit trail and access control reviews.
Data backup and recovery assessments.
Model change control and documentation reviews.
Mock AI audits and inspection readiness support.
CAPA verification and follow-up assessments.

GxP Cellators takes a risk-based approach tailored to the AI application, its intended use, and the relevant GxP processes. The audit scope can consider applicable expectations from authorities such as the FDA, EMA, Health Canada, and MHRA, depending on the organization’s markets and regulatory obligations.

The objective is to provide practical findings that help organizations understand weaknesses, prioritize remediation, and strengthen their compliance processes.

Why Choose GxP Cellators for AI Auditing Services?

Selecting an auditing partner with an understanding of both GxP requirements and AI-related risks can help organizations evaluate complex systems more effectively.

GxP Cellators supports organizations through a structured audit approach that focuses on evidence, risk assessment, documentation, and actionable recommendations.

Key benefits include:

A risk-based approach aligned with the intended use of the AI application.
Review of training and operational data controls.
Assessment of data governance, audit trails, and access management.
Identification of potential compliance gaps.
Practical recommendations for corrective actions.
Support for CAPA follow-up and audit readiness.
Confidential handling of proprietary business and system information, subject to agreed arrangements.

An independent assessment can help organizations gain a clearer understanding of their AI data integrity controls and determine where improvements are needed.

Conclusion

Auditing AI data integrity in a GxP environment requires more than checking whether data is accurate. Organizations must evaluate the complete data lifecycle, including source selection, training data preparation, operational processing, audit trails, access controls, governance, and model changes.

A structured, risk-based audit helps identify weaknesses before they develop into more serious quality or compliance concerns. In addition, documented corrective actions and effectiveness checks help ensure that identified gaps are addressed appropriately.

GxP Cellators supports pharmaceutical and life sciences organizations with specialized AI data integrity audits and related compliance assessments. To discuss your requirements and explore suitable AI auditing services, visit the contact page below.

Contact GxP Cellators: https://www.gxpcellators.com/contact/

Frequently Asked Questions

1. What is AI data integrity?

AI data integrity means maintaining the accuracy, completeness, consistency, traceability, and reliability of data used to train, validate, and operate AI systems. In GxP environments, these controls help support trustworthy records and reliable regulated processes.

2. How is training data integrity assessed?

Training data integrity is assessed by reviewing data sources, completeness, representativeness, preprocessing documentation, potential bias, and data provenance. Auditors also evaluate whether the organization can trace datasets through relevant preparation and training activities.

3. How is operational data integrity assessed?

Operational data integrity is assessed by examining audit trails, access controls, data processing, output traceability, model change documentation, backup procedures, and recovery testing. The scope depends on the system’s intended use and associated risks.

4. What are the ALCOA+ principles in AI data integrity?

ALCOA+ principles describe key characteristics of reliable data: attributable, legible, contemporaneous, original, accurate, complete, consistent, enduring, and available. They can help auditors evaluate relevant AI records and data management controls.

5. Why are audit trails important for AI systems in GxP?

Audit trails help organizations reconstruct relevant activities by recording important events and changes. When appropriately configured and reviewed, they support accountability, investigations, data integrity assessments, and regulatory inspection readiness.

6. How can organizations address AI data integrity gaps?

Organizations should document findings, assess their risks, identify root causes, assign corrective and preventive actions, and define responsible owners and timelines. They should also verify the effectiveness of completed actions and retain supporting evidence.

7. How does GxP Cellators support AI data integrity audits?

GxP Cellators provides support through training data quality audits, operational data integrity assessments, data governance reviews, audit trail evaluations, access control reviews, backup and recovery assessments, mock audits, and CAPA follow-up.

8. How can I contact GxP Cellators for AI data integrity audit support?

Visit the GxP Cellators contact page at https://www.gxpcellators.com/contact/ to discuss your AI data integrity audit requirements and explore relevant auditing support.

by Vinod

13/10/2026

Introduction

Artificial intelligence (AI) is becoming increasingly important in pharmaceutical manufacturing, quality management, clinical research, laboratory operations, and regulatory processes. However, using AI in a regulated environment also introduces risks related to data integrity, system reliability, patient safety, and regulatory compliance.

An AI governance audit checklist helps pharmaceutical companies evaluate whether their AI systems are managed responsibly throughout their lifecycle. It provides a structured way to review governance policies, risk assessments, human oversight, change control, vendor management, and documentation.

In GxP environments, AI governance should also align with applicable quality management systems, computerised system validation or assurance practices, data integrity expectations, and risk-based controls. The appropriate controls depend on the intended use of the AI system and its potential impact on product quality, patient safety, and data reliability.

GxP Cellators provides specialized auditing support for organizations seeking to strengthen their AI governance practices, identify compliance gaps, and improve inspection readiness.

What Is an AI Governance Audit?

An AI governance audit is a systematic assessment of the policies, procedures, responsibilities, controls, and documentation used to manage AI systems. It examines whether an organization has appropriate oversight of how AI solutions are selected, developed, tested, deployed, monitored, updated, and retired.

For pharmaceutical companies, the audit should consider how AI interacts with regulated processes. For example, an AI tool used to organize routine administrative information may have a different risk profile from a system that supports laboratory result interpretation, manufacturing decisions, or product quality assessments.

The purpose is not simply to confirm that an AI system works technically. Instead, the audit evaluates whether the organization can demonstrate appropriate control, traceability, accountability, and ongoing oversight.

Why Is AI Governance Important for Pharmaceutical Companies?

Pharmaceutical companies must maintain reliable processes and trustworthy records. Introducing AI without clear governance can create gaps in accountability, documentation, and risk management.

A structured governance program helps organizations:

Define accountability for AI-related decisions.
Identify and prioritize risks associated with AI applications.
Maintain appropriate human review of critical outputs.
Control changes to models, software, data, and configurations.
Evaluate third-party AI providers and service arrangements.
Protect sensitive information and maintain data integrity.
Establish monitoring and escalation procedures.
Prepare evidence for internal audits and applicable regulatory inspections.

Importantly, AI governance does not replace validation, qualification, or established quality controls. Instead, it helps coordinate these activities within a documented, risk-based management framework.

AI Governance Audit Checklist for Pharmaceutical Companies

The following checklist provides seven essential areas to review during an AI governance audit. Organizations should adapt these questions to their AI applications, quality systems, and applicable regulatory obligations.

1. AI Governance Framework

A documented governance framework establishes how AI systems are evaluated, approved, managed, and monitored across the organization.

During the audit, review the following questions:

Is there a documented AI governance policy or framework?
Has senior management approved the framework?
Does it define the scope of AI applications covered?
Does it address AI systems used in GxP activities?
Are approval and escalation processes clearly documented?
Is the framework reviewed periodically?
Are relevant policies updated when business processes or regulatory expectations change?

What auditors should verify: Review the approved policy, associated procedures, governance meeting records, and evidence of periodic review. Confirm that the framework applies to relevant AI systems rather than existing only as a high-level policy.

2. Roles and Responsibilities

Effective AI governance requires clear accountability. Quality assurance, regulatory affairs, IT, data science, operations, and business teams may all contribute to the oversight of an AI system.

The audit should determine whether:

AI system owners are formally identified.
Quality and compliance responsibilities are documented.
Approval authority is clearly assigned.
An AI oversight committee or equivalent governance body exists where appropriate.
Committee membership reflects the required technical and quality expertise.
Personnel receive suitable training.
Responsibilities are communicated to internal teams and relevant external partners.

What auditors should verify: Examine responsibility matrices, job descriptions, committee charters, training records, and meeting minutes. Check whether personnel understand their responsibilities when an AI system produces unexpected or potentially harmful results.

3. AI System Inventory and Classification

A complete AI inventory helps an organization understand which systems it uses and where governance controls are required. Without an accurate inventory, unapproved or undocumented AI applications may be overlooked.

Review whether:

A centralized inventory of relevant AI systems is maintained.
Each system has a defined owner and intended purpose.
The inventory identifies the system’s supplier or developer.
GxP relevance has been assessed.
Systems are classified according to risk and business impact.
New AI applications are assessed before deployment.
Model versions and significant configuration changes are traceable.
Retired or replaced systems are documented appropriately.

What auditors should verify: Compare the official inventory with information from IT, quality, laboratory, manufacturing, and other relevant departments. Where appropriate, also review approved software lists and supplier records to identify systems missing from the governance process.

4. AI Risk Assessment

Risk assessment is a central part of pharmaceutical AI governance. The level of control should reflect the system’s intended use, complexity, limitations, and potential impact on product quality, patient safety, and data integrity.

The audit checklist should include these questions:

Has each relevant AI system undergone a documented risk assessment?
Is the intended use clearly defined?
Are potential failure modes and foreseeable misuse considered?
Are risks to data integrity, privacy, and system reliability assessed?
Is the potential impact on GxP decisions evaluated?
Are high-risk applications subject to appropriate additional controls?
Are mitigation measures documented and approved?
Are risks reassessed following significant changes or incidents?

What auditors should verify: Review risk assessment reports, approval records, mitigation plans, and evidence that identified controls have been implemented. Confirm that risk classifications are supported by documented reasoning rather than assigned arbitrarily.

5. Change Control and AI Model Updates

AI systems may change through software releases, model updates, revised training data, configuration changes, or changes to their intended use. These changes can affect system performance and reliability.

The audit should establish whether:

AI systems are covered by an appropriate change control process.
Proposed changes are assessed before implementation.
Model and software versions are recorded.
Updates undergo suitable testing and approval.
The potential impact on validated or qualified states is evaluated.
Significant changes trigger risk reassessment where necessary.
Rollback or recovery arrangements are defined when appropriate.
Emergency changes are documented and reviewed.

What auditors should verify: Trace a sample change from its initial request through impact assessment, testing, approval, implementation, and post-implementation review. Check whether the process captures changes made by external AI providers as well as internal teams.

6. Human Oversight and AI Output Review

Human oversight is particularly important when AI outputs influence regulated decisions. Personnel should understand the system’s limitations and know when an output requires additional investigation.

During the audit, assess whether:

Human review requirements are documented.
Personnel can challenge or override AI recommendations where appropriate.
Critical decisions receive the required level of review.
Overrides and interventions are recorded when necessary.
Users understand the system’s intended use and limitations.
Procedures explain how to handle unexpected outputs.
Escalation arrangements exist for potentially incorrect results.
Appropriate training is provided to system users and reviewers.

What auditors should verify: Review relevant procedures, training records, sample decision records, and documented exceptions. Determine whether human oversight is meaningful or whether employees routinely accept AI outputs without appropriate evaluation.

7. AI Vendor and Supplier Management

Third-party AI tools can introduce additional risks because organizations may have limited visibility into model development, data handling, software updates, and supplier controls.

The audit should assess whether:

AI suppliers undergo documented qualification or assessment.
Supplier risks are evaluated according to intended use.
Responsibilities between the organization and supplier are defined.
Contracts or quality agreements address relevant quality obligations where appropriate.
Suppliers provide sufficient technical and compliance documentation.
Data security and confidentiality requirements are addressed.
Supplier changes are communicated and assessed.
Ongoing performance monitoring is established.
Supplier audits are conducted when justified by risk and applicable requirements.

What auditors should verify: Examine supplier assessments, contracts, service descriptions, security documentation, change notifications, and available audit evidence. Confirm that the organization understands which controls remain its responsibility even when an AI service is outsourced.

Additional Areas to Include in an AI Governance Audit

Although the seven checklist areas provide a strong foundation, pharmaceutical organizations should also review supporting controls that affect AI reliability and compliance.

Data Integrity and Documentation

Review how AI-related data is collected, processed, stored, and retained. Where relevant, confirm that records are attributable, legible, contemporaneous, original or appropriately verified, and accurate. Also evaluate access controls, audit trails, record retention, and traceability of important decisions.

The applicable data integrity controls should reflect the system’s intended use and the relevant GxP requirements.

Performance Monitoring and Incident Management

AI governance should continue after deployment. Organizations need procedures for monitoring performance, identifying unexpected behavior, documenting incidents, and escalating significant concerns.

Check whether performance indicators, review frequencies, acceptance criteria, and escalation thresholds are defined where appropriate. Verify that incidents and recurring issues are investigated and that corrective and preventive actions (CAPA) are implemented when required.

Documentation and Audit Trail Review

AI governance decisions should be supported by suitable evidence. Depending on the application, this may include requirements, risk assessments, testing records, approvals, model versions, monitoring reports, and incident investigations.

Auditors should confirm that records are controlled, accessible to authorized personnel, and sufficiently detailed to reconstruct important decisions.

Common Findings During AI Governance Audits

Organizations may encounter several recurring weaknesses when introducing AI into regulated processes.

Missing governance procedures: AI tools are adopted without a clear approval and oversight framework.
Incomplete inventories: Departments use AI applications that are not recorded centrally.
Weak risk assessments: Assessments do not adequately consider the intended use or impact on GxP activities.
Uncontrolled updates: Model or software changes are introduced without appropriate impact assessment.
Insufficient human oversight: Personnel rely on AI outputs without following defined review procedures.
Limited supplier oversight: Organizations lack adequate information about third-party controls or change management.
Poor documentation: Decisions, exceptions, approvals, and corrective actions cannot be reconstructed reliably.
Inadequate monitoring: There is no clear process for detecting performance issues after deployment.

These findings should be evaluated in context. Their significance depends on the application, applicable requirements, and potential impact. Organizations should document each finding, assess its risk, assign responsibility, and establish appropriate corrective actions.

How GxP Cellators Supports AI Governance Audits

GxP Cellators supports pharmaceutical and life sciences organizations with auditing and compliance services designed to help identify weaknesses and strengthen governance practices.

Its AI governance audit support can include:

AI governance framework assessments.
Reviews of roles, responsibilities, and oversight arrangements.
AI system inventory and classification reviews.
AI risk assessment reviews.
Change control and model update reviews.
Human oversight process assessments.
AI vendor and supplier audit support.
Mock AI audits and inspection-readiness assessments.
Documentation and data integrity reviews.
CAPA verification and follow-up.

The scope of each engagement should be tailored to the organization’s AI applications, regulatory environment, and identified risks.

Why Choose GxP Cellators?

GxP Cellators focuses on practical audit support for regulated organizations. Its approach emphasizes identifying control weaknesses, reviewing available evidence, and providing actionable recommendations.

Organizations can discuss their requirements, including relevant FDA, EMA, Health Canada, MHRA, or WHO expectations, depending on their operations and applicable regulatory obligations.

The goal is to help companies understand their current governance position, prioritize remediation activities, and improve oversight of AI systems used in regulated processes.

To discuss your requirements, visit the GxP Cellators Contact Page.

Frequently Asked Questions

1. What should be included in an AI governance audit checklist?

An AI governance audit checklist should cover the governance framework, roles and responsibilities, AI system inventory, risk assessment, change control, human oversight, vendor management, data integrity, documentation, and ongoing performance monitoring. The checklist should be tailored to the intended use and risk of each AI system.

2. Why is AI governance important for pharmaceutical companies?

AI governance helps pharmaceutical companies maintain oversight of AI applications and manage risks involving product quality, patient safety, data integrity, and regulatory compliance. It establishes clear responsibilities, documented controls, and processes for monitoring and managing AI systems throughout their lifecycle.

3. Who should be part of an AI oversight committee?

Depending on the organization’s size and AI applications, an oversight committee may include representatives from quality assurance, regulatory affairs, IT, data science, information security, operations, and relevant business functions. Members should have suitable expertise, clearly defined responsibilities, and appropriate decision-making authority.

4. How often should an AI governance audit be conducted?

The audit frequency should be based on risk, applicable requirements, changes to the AI environment, and the organization’s quality system. Higher-risk applications may require more frequent review. Significant incidents, supplier changes, model updates, or changes in intended use may also trigger additional assessments.

5. What is the difference between AI governance and AI validation?

AI governance defines the policies, responsibilities, oversight, and controls used to manage AI systems. AI validation or an appropriate assurance approach evaluates whether a system meets its intended requirements and is suitable for its intended use. Both activities can be important in regulated environments, but they serve different purposes.

6. How does GxP Cellators support AI governance audits?

GxP Cellators offers AI governance audit support that may include framework assessments, risk assessment reviews, inventory reviews, change control assessments, vendor audit support, mock audits, and CAPA follow-up. The engagement scope can be tailored to the organization’s requirements.

7. How can a pharmaceutical company prepare for an AI governance audit?

Start by identifying relevant AI systems and their intended uses. Gather governance policies, risk assessments, system inventories, change records, supplier documentation, training records, and monitoring evidence. Assign responsible personnel, review open CAPAs, and address significant gaps before the audit.

Contact GxP Cellators for AI Governance Audit Support

A structured AI governance audit checklist can help pharmaceutical companies identify weaknesses before they develop into larger quality or compliance concerns. By reviewing governance responsibilities, system risks, change control, human oversight, and supplier management, organizations can establish a more controlled approach to AI adoption.

GxP Cellators provides specialized auditing support to help organizations assess AI governance practices, identify potential gaps, and plan appropriate improvements.

Contact GxP Cellators: https://www.gxpcellators.com/contact/

by Vinod

13/10/2026

AI-Governance-and-Data-Integrity-Audits-in-GxP-1280x720.webp

Introduction

Artificial intelligence (AI) is increasingly being used across pharmaceutical manufacturing, laboratory operations, clinical research, quality management, and regulatory processes. Although AI can improve efficiency and support better decision-making, its use in regulated environments also introduces new compliance challenges.

In 2026, AI governance and data integrity remain important considerations for organizations operating under Good Manufacturing Practices (GMP), Good Laboratory Practices (GLP), Good Clinical Practices (GCP), and other GxP requirements. Companies must understand how AI systems are developed, validated, monitored, and maintained throughout their lifecycle.

AI governance and data integrity audits in GxP help organizations assess whether AI applications operate under appropriate controls and whether the data they process remains reliable, traceable, and protected from unauthorized changes.

GxP Cellators provides specialized auditing and compliance support to help pharmaceutical and life sciences organizations identify risks, review documentation, and strengthen their AI governance frameworks.

This guide explains AI governance, data integrity requirements, essential audit checklist items, common compliance risks, and how professional AI auditing services can support GxP compliance.

What Is AI Governance in GxP?

AI governance is the framework of policies, procedures, responsibilities, and oversight mechanisms used to manage AI systems throughout their lifecycle. In a regulated environment, this framework should ensure that AI applications are appropriately assessed, documented, monitored, and controlled.

Unlike general business applications, AI systems used in GxP processes may influence product quality, laboratory results, clinical data, manufacturing decisions, or patient safety. Therefore, organizations should establish governance controls that reflect the intended use and potential risks of each application.

Key Elements of GxP AI Governance

An effective AI governance framework should include the following elements:

AI system inventory: Maintain a documented list of AI tools and applications used in regulated processes.
Risk assessment: Evaluate the potential impact of each AI system on product quality, data integrity, patient safety, and regulatory compliance.
Defined responsibilities: Assign clear accountability for system ownership, validation, monitoring, and approval.
Governance oversight: Establish appropriate review and escalation processes for AI-related risks.
Change control: Assess and document model updates, configuration changes, and modifications to data sources.
Human oversight: Define when qualified personnel must review, approve, or override AI-generated recommendations.
Vendor management: Evaluate third-party AI providers, their documentation, security controls, and support arrangements.
Lifecycle monitoring: Review system performance and suitability throughout its operational life.

These controls help organizations understand how AI systems are used and ensure that important decisions remain appropriately governed.

What Is Data Integrity for AI Systems?

Data integrity refers to the accuracy, completeness, consistency, and reliability of data throughout its lifecycle. For AI applications, this includes the data used to train, configure, test, and operate a model, as well as the inputs and outputs generated during routine use.

Poor data quality can lead to unreliable AI recommendations, inaccurate predictions, and potentially unsuitable decisions. In regulated environments, these problems may also affect the reliability of records used to demonstrate compliance.

Important Data Integrity Controls for AI

Organizations should evaluate several areas when reviewing AI data integrity:

Training data quality: Confirm that data is suitable for its intended purpose and has appropriate quality controls.
Audit trails: Maintain suitable records of relevant inputs, outputs, user activities, and system changes.
Access controls: Restrict system and data access according to assigned responsibilities.
Model documentation: Record relevant model versions, configurations, updates, and approvals.
Data traceability: Maintain sufficient information to understand where data originated and how it was processed.
Backup and recovery: Establish appropriate measures to protect important records and support recovery.
Output review: Define how AI-generated results are reviewed, verified, and approved when necessary.

These controls should be proportionate to the system’s intended use and risk. Not every AI application requires identical controls, but regulated organizations should be able to justify their approach.

Understanding ALCOA+ Principles in AI Data Integrity

ALCOA+ is a widely used framework for evaluating data integrity in regulated industries. Its principles can help organizations assess whether records generated or processed by AI systems are trustworthy.

The principles include:

Attributable: Records identify who performed an action or which system generated the information.
Legible: Records remain readable and understandable throughout their retention period.
Contemporaneous: Information is recorded at the time the activity occurs or in accordance with applicable requirements.
Original: Original records or appropriately verified true copies are retained as required.
Accurate: Data and records correctly represent the activity or result.
Complete: Relevant data, including necessary metadata and associated records, is retained.
Consistent: Records follow an appropriate chronological and logical sequence.
Enduring: Records remain accessible and protected throughout their required retention period.
Available: Records can be retrieved when needed for review, investigation, or inspection.

During AI data integrity audits, these principles can help auditors assess input records, model outputs, audit trails, and supporting documentation. However, applying ALCOA+ alone does not establish full compliance; organizations must also consider applicable regulations, system requirements, and intended use.

AI Governance and Data Integrity Audit Checklist

A structured checklist helps organizations evaluate whether their AI systems have suitable governance and data integrity controls. The following areas can support internal assessments and audit preparation.

1. AI Governance Review

Check whether:

A documented AI governance framework is available.
All relevant AI systems are identified in an inventory.
Roles and responsibilities are clearly assigned.
AI-related risks are included in appropriate quality risk management activities.
Procedures exist for approving new AI applications.
Model updates and significant changes follow documented change control.
Human oversight requirements are clearly defined.
AI-related incidents are recorded, investigated, and escalated.
Third-party AI tools are assessed before use.
Periodic reviews evaluate whether systems remain suitable for their intended purpose.

2. Data Integrity Review

Check whether:

AI inputs and outputs are recorded appropriately for their intended use.
Relevant audit trails are enabled and protected.
User access is controlled and periodically reviewed.
Training and operational data have suitable quality controls.
Data sources and transformations are sufficiently traceable.
Model changes are documented and approved.
Data integrity issues can be detected and investigated.
Records meet applicable ALCOA+ expectations.
Backup, recovery, and retention arrangements are documented.
AI-generated results are reviewed when required by risk or procedure.

3. Validation and Documentation Review

AI systems used in regulated processes should be assessed according to their intended use, potential risks, and applicable requirements.

Auditors may review:

User requirements and intended-use documentation.
Risk assessments and validation plans.
Testing records and acceptance criteria.
Model configuration and version history.
Change control and approval records.
Procedures for monitoring system performance.
Training records for relevant personnel.
Incident management and corrective action documentation.

The exact documentation required depends on the application, its impact on regulated activities, and the applicable regulatory framework.

Common AI Governance and Data Integrity Audit Findings

Organizations may encounter several recurring weaknesses when reviewing AI applications in GxP environments.

Incomplete AI System Inventory

Some organizations introduce AI tools through different departments without maintaining a complete inventory. As a result, quality teams may not know which applications influence regulated processes.

A documented inventory, supported by periodic reviews, can improve visibility and accountability.

Weak Change Control

AI models, software configurations, and connected data sources may change over time. If changes are introduced without appropriate assessment and documentation, the organization may lose confidence in the system’s validated state.

A risk-based change control process should determine which changes require additional testing, review, approval, or revalidation.

Insufficient Data Traceability

When organizations cannot explain where data originated or how an AI system processed it, investigating unexpected results becomes difficult.

Appropriate metadata, audit trails, and documented data flows can help establish traceability.

Unclear Human Oversight

AI-generated outputs should not automatically replace qualified human judgment in situations where review or approval is required.

Organizations should define responsibilities, escalation procedures, and review criteria according to the risks associated with each application.

Inadequate Vendor Oversight

Third-party AI platforms may introduce risks related to data access, system changes, documentation, and transparency.

Supplier assessments should consider relevant technical controls, contractual responsibilities, change notifications, and access to evidence needed to support compliance.

How to Prepare for an AI Governance and Data Integrity Audit

Preparation should begin before an internal or external audit is scheduled. A structured approach helps organizations identify weaknesses and collect relevant evidence.

Step 1: Identify AI Applications

Create an inventory of AI systems used in manufacturing, laboratory operations, quality management, clinical research, and other relevant processes.

Step 2: Assess Compliance Risks

Evaluate each application according to its intended purpose and potential impact on product quality, patient safety, data integrity, and regulated decisions.

Step 3: Review Policies and Procedures

Check whether governance, validation, access control, change management, incident handling, and data integrity procedures adequately address the relevant AI applications.

Step 4: Examine Supporting Evidence

Review system documentation, risk assessments, testing records, audit trails, training records, approvals, and supplier documentation.

Step 5: Identify and Prioritize Gaps

Document identified weaknesses, assess their potential impact, and prioritize corrective actions based on risk.

Step 6: Develop a CAPA Plan

Establish corrective and preventive actions (CAPA) with assigned owners, target dates, and clear completion criteria. Verify that completed actions address the identified problems.

Step 7: Conduct Follow-Up Reviews

Review the effectiveness of implemented controls and confirm that unresolved issues are managed appropriately.

Regulatory Considerations for AI Governance in GxP

AI governance must be considered alongside the regulations and quality requirements applicable to the organization’s operations. Relevant considerations may include FDA requirements, European Medicines Agency (EMA) expectations, Health Canada requirements, MHRA guidance, and applicable World Health Organization (WHO) guidance.

The specific obligations depend on the application, jurisdiction, and regulated activity. For example, AI used in a manufacturing quality decision may require a different assessment from AI used for general administrative support.

Organizations should also evaluate applicable requirements for computerized systems, electronic records, data integrity, validation, risk management, and quality oversight.

Importantly, there is no single universal AI audit checklist that guarantees compliance in every GxP environment. Companies should assess applicable requirements and document how their controls address identified risks.

How GxP Cellators Supports AI Governance and Data Integrity Audits

GxP Cellators provides specialized auditing and compliance support for pharmaceutical and life sciences organizations seeking to strengthen governance over AI applications.

Its AI governance and data integrity audit services can help organizations evaluate existing controls, identify compliance gaps, and develop practical improvement plans.

Our AI Governance and Data Integrity Audit Services Include

AI governance framework assessments.
Data integrity audits for AI systems.
Training data quality audits.
AI model validation documentation reviews.
Human oversight process audits.
AI vendor and supplier audits.
Regulatory compliance reviews.
Mock AI audits.
CAPA verification and follow-up.

Why Choose GxP Cellators?

GxP Cellators focuses on a risk-based approach that considers the intended use of AI systems and their impact on regulated operations.

Organizations can benefit from:

Auditing support focused on GxP quality and compliance.
Assessments tailored to relevant AI applications.
Reviews of documentation, governance, and data integrity controls.
Practical findings and recommendations for addressing identified gaps.
Support for regulatory readiness and corrective action follow-up.
Appropriate confidentiality when handling proprietary business and system information.

An independent audit can help organizations understand where controls may need improvement before those weaknesses affect regulated operations.

Benefits of AI Governance and Data Integrity Audits

A well-planned audit can deliver benefits beyond identifying documentation gaps.

Improved regulatory readiness: Organizations can identify weaknesses before an inspection or formal assessment.

Stronger data reliability: Reviews can highlight weaknesses in data traceability, access controls, audit trails, and record management.

Better risk management: Risk-based assessments help organizations prioritize issues according to their potential impact.

Clearer accountability: Defined governance responsibilities make it easier to manage AI systems and investigate incidents.

More effective change management: Documented review and approval processes help maintain appropriate control over model updates and system modifications.

Stronger supplier oversight: Vendor assessments can improve visibility into third-party risks and supporting compliance evidence.

These benefits depend on implementing appropriate corrective actions and maintaining effective controls after the audit.

Frequently Asked Questions

1. What is AI governance in GxP?

AI governance in GxP is the framework of policies, procedures, risk assessments, and oversight mechanisms used to manage AI systems in regulated environments. It covers system inventory, responsibilities, change control, human oversight, supplier management, and ongoing monitoring.

2. What is data integrity for AI systems?

Data integrity for AI systems means ensuring that relevant data remains accurate, complete, consistent, traceable, and protected throughout its lifecycle. Controls may include access restrictions, audit trails, training data quality reviews, model documentation, and ALCOA+ principles.

3. Why are AI governance and data integrity audits important?

These audits help organizations identify weaknesses in AI oversight, data handling, documentation, validation, and change management. Addressing those weaknesses can improve regulatory readiness and help protect the reliability of information used in GxP processes.

4. What should an AI governance audit checklist include?

An AI governance audit checklist should cover system inventory, risk assessment, roles and responsibilities, change control, human oversight, supplier management, data integrity, validation documentation, audit trails, incident handling, and CAPA follow-up.

5. How does ALCOA+ apply to AI systems?

ALCOA+ provides data integrity principles that can be applied to relevant records associated with AI systems. Auditors can use these principles to assess attribution, readability, contemporaneous recording, originality, accuracy, completeness, consistency, durability, and availability.

6. How does GxP Cellators support AI governance and data integrity audits?

GxP Cellators provides AI governance framework assessments, AI data integrity audits, training data quality reviews, model validation documentation assessments, supplier audits, mock audits, regulatory compliance reviews, and CAPA follow-up support.

7. How can a pharmaceutical company prepare for an AI audit?

A pharmaceutical company can prepare by identifying AI applications, assessing risks, reviewing governance procedures, organizing validation and data integrity evidence, evaluating suppliers, and addressing identified gaps through documented corrective actions.

8. How can I contact GxP Cellators for AI auditing services?

Organizations interested in AI governance and data integrity audit support can contact GxP Cellators through its official contact page to discuss their requirements and potential compliance support.

Contact GxP Cellators

AI technologies can support pharmaceutical and life sciences operations, but their use in regulated environments requires appropriate governance, documentation, and data integrity controls.

By conducting structured AI governance and data integrity audits, organizations can identify weaknesses, strengthen oversight, and improve their readiness for regulatory review.

GxP Cellators supports organizations through specialized auditing services, risk-based assessments, documentation reviews, and CAPA follow-up.

Contact GxP Cellators: https://www.gxpcellators.com/contact/

Discuss your AI governance, data integrity, and GxP auditing requirements with the team to explore suitable support for your organization.

by Vinod

13/10/2026

Introduction

Artificial intelligence (AI) is becoming increasingly important in pharmaceutical manufacturing, biotechnology, clinical research, and other regulated industries. Organizations are using AI to analyze data, support quality decisions, improve processes, and automate specific activities. However, when AI systems are used in GxP-regulated environments, organizations must ensure that these technologies operate reliably and meet applicable compliance requirements.

Risk-based AI CSV audits help organizations evaluate computerized systems according to their potential impact on patient safety, product quality, data integrity, and regulatory compliance. Instead of applying the same audit approach to every system, this method directs attention and resources toward areas with the greatest potential risk.

Computerized System Validation (CSV) traditionally focuses on demonstrating that computerized systems perform as intended. AI-enabled systems can introduce additional challenges because their outputs may depend on training data, model design, configuration, ongoing monitoring, and changes over time.

Therefore, GxP organizations need a structured approach to AI CSV risk assessment and auditing. In this guide, GxP Cellators explains the key steps involved in planning, conducting, and maintaining risk-based AI CSV audits.

What Are Risk-Based AI CSV Audits?

Risk-based AI CSV audits are structured assessments that examine AI-enabled computerized systems according to their intended use, criticality, and potential impact on regulated operations.

The objective is to determine whether appropriate controls, validation evidence, documentation, and monitoring processes are in place. Auditors also evaluate whether organizations can identify, assess, and manage risks associated with AI functionality.

For example, an AI tool that helps organize non-critical administrative information may require a different level of oversight from an AI system that influences batch release decisions, laboratory results, or other product-quality activities.

A risk-based approach helps organizations establish proportionate controls without overlooking important compliance responsibilities.

Why Are AI CSV Audits Important in GxP Environments?

AI systems can introduce risks that are not always addressed adequately by conventional software testing alone. These risks may involve unreliable outputs, biased or incomplete training data, insufficient documentation, unauthorized changes, or limited traceability.

A structured audit can help organizations evaluate whether:

The AI system has a clearly defined intended use.
Its use within GxP processes has been appropriately assessed.
Validation activities reflect the system’s intended purpose and risks.
Data integrity controls protect records throughout their lifecycle.
AI-generated outputs are reviewed appropriately.
Changes to models, data, or configurations are controlled.
Responsibilities for system oversight are clearly assigned.

The audit approach should reflect the actual system and its regulated use rather than assuming that every AI application presents the same level of risk.

Step-by-Step Guide to Risk-Based AI CSV Audits

Step 1: Identify and Inventory AI Systems

The first step is to identify all AI-enabled systems used in GxP-regulated activities. Organizations may have AI functionality embedded in commercial software, laboratory platforms, manufacturing systems, analytics tools, or internally developed applications.

A complete inventory should include:

System name and description.
Intended use and business purpose.
Associated GxP processes.
System owner and relevant stakeholders.
Data sources and integrations.
Validation status and available documentation.
AI model or software components, where applicable.

This inventory provides the foundation for risk assessment and audit planning. It also helps organizations identify systems that may have been introduced without sufficient quality oversight.

Step 2: Perform an AI CSV Risk Assessment

Once the inventory is complete, organizations should evaluate the risks associated with each system. The assessment should consider both the potential consequences of system failure and the effectiveness of existing controls.

Important risk factors include:

Patient safety: Could an incorrect AI output influence a decision that affects patient safety?

Product quality: Could the system affect manufacturing parameters, laboratory results, quality investigations, or product release decisions?

Data integrity: Could AI processing compromise the accuracy, completeness, consistency, or traceability of GxP records?

Regulatory compliance: Could the system create gaps in validation evidence, documentation, access control, or required oversight?

System complexity: Does the system use changing models, multiple integrations, external data sources, or complex decision-making processes?

Organizations should document the rationale behind their risk ratings. A risk matrix can help compare systems consistently, although the final assessment should reflect the intended use and relevant controls.

Step 3: Prioritize Audits According to Risk

After assessing the risks, organizations can establish an audit schedule based on system criticality, previous findings, control effectiveness, and the consequences of failure.

A practical classification may include the following levels:

High-risk systems: Systems with significant potential effects on patient safety, product quality, or critical GxP decisions. These generally require stronger oversight and more frequent review.
Medium-risk systems: Systems with a meaningful but more limited impact, supported by appropriate controls. Periodic audits should verify that these controls remain effective.
Low-risk systems: Systems with limited impact on regulated activities. Audits may be less frequent, depending on the documented risk assessment and applicable procedures.

These categories are examples rather than universal regulatory classifications. Organizations should establish their own criteria and audit frequencies through approved quality procedures.

Audits should also be reconsidered after significant system changes, major incidents, recurring deviations, or new information that changes the risk profile.

Step 4: Define the Audit Scope

A clear audit scope helps ensure that the assessment covers the most important risks. The scope should be based on the system’s intended use, risk assessment, applicable requirements, and previous audit findings.

Depending on the system, the audit may examine:

Validation strategy and supporting evidence.
User requirements and functional specifications.
AI model documentation and intended-use limitations.
Training, testing, and operational data quality.
Access controls and data integrity safeguards.
Change management and configuration controls.
AI output review and human oversight.
Incident management and deviation handling.
Supplier documentation and third-party responsibilities.
Periodic review and ongoing performance monitoring.

Not every audit requires the same depth of investigation. High-risk functions may need more detailed testing, stronger evidence, and closer examination of how AI outputs influence regulated decisions.

Step 5: Conduct the AI CSV Audit

During the audit, auditors compare documented procedures with actual practices. They review evidence, interview relevant personnel, examine system records, and assess whether established controls work as intended.

A structured audit process should include:

Reviewing system documentation and the approved validation approach.
Confirming that the documented intended use matches actual use.
Examining risk assessments and control measures.
Checking validation evidence and test coverage.
Reviewing data integrity, access controls, and audit trails where applicable.
Evaluating change control and incident management.
Assessing human oversight of AI-generated outputs.
Recording findings with supporting evidence.

Audit findings should clearly explain the issue, the relevant evidence, the potential impact, and the required follow-up. This makes it easier for system owners and quality teams to prioritize corrective actions.

Step 6: Manage Findings Through CAPA

Identifying audit findings is only one part of the process. Organizations must also determine the underlying causes and implement appropriate corrective and preventive actions (CAPA).

For example, an audit may identify incomplete documentation for an AI model update. The immediate correction may involve completing the required records. However, the underlying cause could be an unclear change-control procedure or insufficient staff training.

An effective CAPA process should include:

Clear descriptions of findings.
Documented root-cause analysis.
Corrective and preventive action plans.
Assigned responsibilities and completion dates.
Assessment of potential effects on existing GxP records or decisions.
Verification that actions were implemented.
Effectiveness checks where appropriate.

Critical issues should be escalated through the organization’s established quality and compliance procedures. Closure should be supported by evidence rather than relying only on statements that corrective actions are complete.

Step 7: Monitor and Review AI Systems Continuously

AI CSV risk assessments should not remain unchanged throughout a system’s lifecycle. A system’s risk profile may change when new data sources are introduced, models are updated, workflows change, or the system is used for additional purposes.

Organizations should establish monitoring and periodic review processes that consider:

Changes to AI models and software components.
Data quality issues and unexpected outputs.
Deviations, incidents, and recurring complaints.
Changes in intended use or GxP impact.
Supplier updates and relevant service changes.
Outstanding audit findings and CAPA effectiveness.
New or revised regulatory expectations.

These reviews help organizations determine whether additional validation, risk assessment, or auditing is necessary.

Key Challenges in AI CSV Auditing

Although risk-based auditing can improve oversight, AI-enabled systems may present several challenges.

Limited Transparency

Some AI models are difficult to interpret. Organizations should therefore document their intended use, limitations, performance criteria, and decision-making boundaries as appropriate. Where full interpretability is not possible, alternative controls and documented oversight may be needed.

Training Data Quality

Incomplete, inaccurate, or unsuitable data can affect AI performance. Auditors should examine relevant data governance procedures, data suitability assessments, and controls over data changes.

Model and Software Changes

Updates can alter system behavior. Organizations should assess changes according to their potential impact and determine whether additional testing, validation, or approval is required.

Inadequate Documentation

Missing risk assessments, unclear responsibilities, or incomplete validation records can make it difficult to demonstrate that an AI system is controlled. Documentation should provide traceable evidence of decisions, testing, approvals, and ongoing oversight.

Third-Party AI Solutions

External software providers may control important elements of an AI solution. Organizations should evaluate supplier documentation, responsibilities, change notifications, and available evidence while retaining appropriate oversight of their own GxP use.

How GxP Cellators Supports Risk-Based AI CSV Audits

GxP Cellators provides auditing and compliance support for organizations working in regulated life sciences environments. Its risk-based AI CSV audit services can help organizations evaluate computerized systems, identify compliance gaps, and strengthen their validation and governance practices.

Depending on the project’s scope and requirements, support may include:

AI system inventory and risk assessment.
Risk-based audit planning.
Comprehensive AI CSV audits.
Pre-audit readiness assessments.
AI governance framework reviews.
Training data quality audits.
AI model validation documentation reviews.
Data integrity audits.
Mock inspection support.
CAPA verification and follow-up.

The objective is to provide practical findings that help organizations understand weaknesses, prioritize remediation, and maintain appropriate controls throughout the system lifecycle.

Why Choose GxP Cellators?

Organizations need an audit approach that considers both computerized system validation and the specific challenges of AI technology.

GxP Cellators focuses on risk-based assessments, actionable reporting, and compliance considerations relevant to regulated environments. Its services can support organizations preparing for audits, reviewing AI governance, or evaluating the effectiveness of existing validation controls.

The scope of any engagement should be agreed in advance, including the systems covered, applicable requirements, expected deliverables, and confidentiality arrangements.

To discuss your requirements, visit the GxP Cellators Contact Page.

Best Practices for Effective Risk-Based AI CSV Audits

Organizations can strengthen their audit programs by following these practical recommendations:

Maintain an up-to-date inventory of AI-enabled GxP systems.
Define documented, risk-based criteria for audit prioritization.
Establish clear ownership for validation, quality, and AI governance.
Maintain traceable evidence for risk assessments and validation activities.
Evaluate data integrity and human oversight controls.
Apply change management to model, software, and intended-use changes.
Track findings through a formal CAPA process.
Reassess risk after significant changes or incidents.
Review applicable regulatory guidance before defining compliance expectations.
Keep audit schedules proportionate to system risk and control effectiveness.

These practices help integrate AI CSV auditing into the wider pharmaceutical quality management system instead of treating it as a separate, one-time activity.

Frequently Asked Questions

1. What is a risk-based AI CSV audit?

A risk-based AI CSV audit evaluates AI-enabled computerized systems according to their potential impact on patient safety, product quality, data integrity, and regulatory compliance. It directs audit effort toward the most significant risks.

2. How is risk assessed for AI systems in GxP environments?

Risk is assessed by examining intended use, GxP impact, system complexity, data quality, AI outputs, existing controls, and the potential consequences of failure. Organizations should document the assessment and its rationale.

3. How often should high-risk AI systems be audited?

Audit frequency should be established through a documented risk assessment and approved quality procedures. High-risk systems generally require closer oversight, with additional reviews after significant changes, incidents, or emerging compliance concerns.

4. How are AI CSV audits different from traditional CSV audits?

Traditional CSV audits evaluate computerized system controls and evidence that the system performs as intended. AI CSV audits may also need to examine model-related risks, training data, output reliability, human oversight, and changes that affect AI behavior.

5. What documents are reviewed during an AI CSV audit?

Depending on the system, auditors may review intended-use documentation, risk assessments, user requirements, validation plans and reports, test evidence, data governance procedures, change-control records, supplier documentation, and CAPA records.

6. Why are data integrity audits important for AI systems?

AI systems may process large volumes of data and generate outputs that influence regulated decisions. Data integrity audits help assess whether relevant records remain accurate, complete, traceable, and protected against unauthorized changes.

7. How does GxP Cellators support risk-based AI CSV audits?

GxP Cellators offers support that may include AI system risk assessments, audit planning, AI CSV audits, governance reviews, validation documentation reviews, data integrity assessments, mock inspections, and CAPA follow-up.

8. How can an organization request AI CSV audit support?

Organizations can contact GxP Cellators through its official contact page to discuss their systems, compliance objectives, audit scope, and support requirements.

Conclusion

Risk-based AI CSV audits help GxP organizations evaluate AI-enabled systems in a structured and proportionate manner. By identifying critical systems, assessing potential risks, prioritizing audit activities, and monitoring corrective actions, organizations can strengthen oversight of AI technologies used in regulated operations.

An effective approach combines documented risk assessments, appropriate validation evidence, data integrity controls, change management, and ongoing monitoring. Because AI systems and their intended uses can evolve, organizations should review their controls throughout the system lifecycle.

GxP Cellators supports organizations seeking practical AI CSV auditing and compliance solutions. Visit the GxP Cellators Contact Page to discuss your risk-based AI CSV audit requirements.

by Vinod

13/10/2026

Introduction

Artificial intelligence (AI) is changing how pharmaceutical companies manage data, automate processes, analyse information, and support critical business decisions. However, introducing AI into regulated computerized systems also creates new challenges for Computerized System Validation (CSV) and GxP compliance.

Traditional CSV approaches focus on demonstrating that computerized systems consistently perform their intended functions. AI-based systems can behave differently because their outputs may depend on training data, model design, changing inputs, and algorithmic behaviour. As a result, pharmaceutical companies must carefully evaluate how these systems are validated, monitored, and maintained throughout their lifecycle.

Understanding AI and CSV validation challenges is essential for protecting data integrity, maintaining product quality, and supporting regulatory compliance. Companies must also establish appropriate documentation, risk management, change control, and human oversight procedures.

In this guide, GxP Cellators explains five major AI validation challenges and practical approaches for addressing them in pharmaceutical and other regulated life sciences environments.

What Is the Relationship Between AI and Computerized System Validation?

Computerized System Validation is a documented process used to demonstrate that a computerized system is suitable for its intended use. In pharmaceutical environments, validation helps ensure that systems operate reliably and protect product quality, patient safety, and data integrity.

AI can be integrated into various regulated activities, including quality control, manufacturing, laboratory analysis, pharmacovigilance, document review, and quality management systems.

For example, an AI-powered system might analyse laboratory results, identify unusual manufacturing patterns, or assist with reviewing quality records. If its output influences a GxP decision, the company must evaluate the system’s intended use and potential impact on regulated activities.

AI validation therefore requires more than testing conventional software functions. Organizations must also assess model performance, data quality, output variability, explainability, and the controls used to manage changes.

Challenge 1: Non-Deterministic AI Outputs

One of the major AI and CSV validation challenges is non-deterministic behaviour. Some AI systems may generate different outputs when given the same input, depending on model configuration, sampling methods, contextual information, or other technical factors.

For example, an AI tool used to summarize deviation reports might produce slightly different summaries for repeated requests. In a regulated environment, the company must determine whether those variations could affect the accuracy or reliability of the final decision.

How to Address Non-Deterministic Outputs

1. Define clear acceptance criteria

Organizations should establish measurable acceptance criteria based on the system’s intended use. These criteria should identify acceptable output variations and define which errors could affect product quality, patient safety, or data integrity.

2. Test the system across multiple runs

Testing should include repeated executions, representative inputs, boundary conditions, and challenging scenarios. This helps organizations understand how consistently the model performs under defined conditions.

3. Establish human review controls

Where AI outputs influence important GxP decisions, qualified personnel should review the results according to documented procedures. The level of review should reflect the associated risk.

4. Implement ongoing performance monitoring

Monitoring helps identify unexpected changes in output quality, accuracy, or consistency. Companies should document deviations from expected performance and investigate significant issues.

Challenge 2: Continuous Learning and Model Changes

Some AI systems can be updated or retrained using new data. Even when a model does not learn automatically during operation, developers may periodically release updated versions.

These changes can affect how the system processes information and produces results. Consequently, a model that performed acceptably during initial validation might behave differently after an update.

Uncontrolled changes can create compliance risks, particularly when the system supports manufacturing decisions, laboratory operations, quality investigations, or other GxP activities.

How to Manage Continuous Learning

1. Establish formal change control

Every relevant model update, configuration change, or modification to training data should be assessed through an appropriate change control process. The assessment should document the reason for the change and its potential impact.

2. Define revalidation triggers

Organizations should establish criteria for determining when additional testing or revalidation is necessary. Triggers may include significant changes to the model, intended use, underlying data, or risk profile.

3. Maintain model version records

Companies should document model versions, approval status, relevant configurations, and the associated validation evidence. This makes it easier to establish which version was used when a particular result was generated.

4. Monitor performance after changes

Following an approved update, organizations should verify that the system continues to meet its intended requirements. Monitoring should include relevant performance indicators and documented procedures for investigating unexpected results.

Challenge 3: Lack of Transparency and Explainability

Some AI models are difficult to interpret because their outputs result from complex relationships within the model. This can make it challenging for pharmaceutical companies to understand why a particular recommendation or prediction was generated.

For regulated organizations, unexplained outputs may create difficulties during internal audits, regulatory inspections, and quality investigations. Companies need sufficient information to evaluate whether an AI system is suitable for its intended use.

The level of explainability required depends on the system’s function, complexity, and potential impact on GxP decisions.

How to Improve AI Transparency

1. Document the model and its intended use

Validation documentation should describe the model’s purpose, intended users, relevant limitations, assumptions, and operating conditions. Where appropriate, organizations should also document the model’s architecture and key configuration details.

2. Establish explainability requirements

Companies should determine what information users need to understand and evaluate model outputs. For high-impact applications, this may include explanations of important contributing factors, known limitations, and conditions in which the model may perform poorly.

3. Implement human oversight

Qualified personnel should be able to review relevant outputs, identify questionable recommendations, and escalate concerns. Responsibilities for accepting, rejecting, or overriding AI recommendations should be clearly defined.

4. Maintain traceable records

Organizations should retain appropriate records of inputs, outputs, model versions, reviews, and decisions. These records support investigations and help demonstrate that the system operates under controlled conditions.

Challenge 4: Data Dependency and Data Integrity

AI models depend heavily on the quality, relevance, and representativeness of their data. Incomplete, inaccurate, outdated, or biased training data can reduce model performance and lead to unreliable results.

For pharmaceutical companies, data quality is particularly important when AI systems interact with laboratory records, manufacturing data, quality events, or regulated documentation.

Poor data governance can also make it difficult to demonstrate where information originated, whether it was modified, and how it was used by the system.

How to Address Data-Related Challenges

1. Validate training and input data

Organizations should define data quality requirements and evaluate whether datasets are appropriate for the intended application. Relevant checks may include completeness, accuracy, consistency, representativeness, and suitability.

2. Establish data governance procedures

Documented governance procedures should define data ownership, access permissions, review responsibilities, retention requirements, and processes for correcting identified errors.

3. Maintain data provenance

Companies should preserve appropriate information about data sources, transformations, preparation methods, and subsequent use. Traceability supports investigations and helps demonstrate how the model’s results were produced.

4. Apply data integrity controls

Access controls, audit trails, backup procedures, and other appropriate safeguards should be evaluated according to the system’s risks and applicable requirements.

5. Monitor data and model performance

Changes in source data or operating conditions may affect model reliability. Organizations should establish monitoring and investigation procedures for significant performance changes or suspected data integrity issues.

Challenge 5: Regulatory Uncertainty and Evolving Expectations

AI technology is developing rapidly, and regulatory expectations may vary according to the application, jurisdiction, and potential impact on regulated activities.

Pharmaceutical companies must determine how applicable requirements and established GxP principles apply to their AI-enabled systems. They should not assume that using a new technology removes the need for appropriate validation, documentation, risk management, or oversight.

Instead, organizations should adopt a risk-based approach that considers the system’s intended use and its potential effect on product quality, patient safety, and data integrity.

How to Address Regulatory Uncertainty

1. Monitor relevant regulatory developments

Companies should review applicable guidance and regulatory updates from authorities such as the FDA, EMA, Health Canada, and MHRA, where relevant to their operations.

2. Apply risk-based validation

Validation activities should be proportionate to the system’s intended use and associated risks. Systems that directly influence critical GxP decisions may require more extensive controls and evidence than lower-risk administrative applications.

3. Maintain complete documentation

Organizations should document requirements, risk assessments, testing, approvals, changes, deviations, and ongoing monitoring activities as appropriate.

4. Review supplier and third-party controls

When an AI solution is supplied by an external vendor, companies should evaluate the vendor’s documentation, security controls, change notification practices, and ability to support validation activities.

5. Seek qualified compliance guidance

Specialist support can help organizations identify gaps, clarify validation responsibilities, and develop an appropriate compliance strategy for their AI-enabled systems.

How GxP Cellators Helps Address AI and CSV Validation Challenges

GxP Cellators supports regulated organizations with GxP auditing and compliance-related services. Companies evaluating AI-enabled computerized systems may benefit from a structured review of their validation approach, documentation, data controls, and governance processes.

The scope of any engagement should be tailored to the system, intended use, applicable requirements, and risks identified.

AI and CSV Audit Support Services

GxP Cellators can support relevant review activities, including:

AI CSV validation strategy reviews.
Computerized system validation documentation reviews.
AI model validation audits.
Training data quality audits.
Data integrity audits.
Human oversight process reviews.
Regulatory compliance reviews.
Mock inspection support.
Corrective and Preventive Action (CAPA) verification and follow-up.

Why Choose GxP Cellators?

Risk-based approach: Reviews can be tailored to the system’s intended use and potential GxP impact.

Practical recommendations: Audit findings can help organizations identify weaknesses and prioritize corrective actions.

Regulatory awareness: Applicable expectations from relevant authorities can be considered within the agreed audit scope.

Documentation focus: Reviews can assess whether validation records, change control documentation, and supporting evidence are appropriate for the intended use.

Confidentiality: Appropriate confidentiality arrangements are important when reviewing proprietary systems, sensitive records, and business information.

Organizations should confirm the scope, deliverables, and applicable regulatory coverage with GxP Cellators before engaging its services.

Best Practices for Validating AI-Enabled GxP Systems

Although each AI application requires an individual assessment, several practices can help pharmaceutical companies build a more effective validation strategy.

Define the intended use: Clearly document what the AI system does, who uses it, and how its outputs influence regulated activities.
Conduct a risk assessment: Identify possible effects on product quality, patient safety, data integrity, and regulatory compliance.
Establish measurable requirements: Define performance expectations and acceptance criteria before testing begins.
Evaluate data quality: Verify that the data used for training, testing, and operation is suitable for the intended purpose.
Maintain lifecycle documentation: Record validation activities, approvals, model versions, changes, and relevant investigations.
Control system changes: Use documented procedures to assess updates and determine whether additional testing is needed.
Provide appropriate oversight: Ensure that qualified personnel understand the system’s limitations and their responsibilities.
Monitor performance: Establish procedures for detecting unexpected results, investigating issues, and implementing corrective actions.

These practices help organizations integrate AI into regulated workflows without overlooking established CSV and GxP compliance principles.

Frequently Asked Questions

1. What are the key validation challenges for AI and CSV?

The main challenges include non-deterministic outputs, continuous learning, limited model transparency, data dependency, and evolving regulatory expectations. Organizations should address these through risk-based validation, documented change control, data governance, and ongoing performance monitoring.

2. How can non-deterministic AI outputs be validated?

Companies can define acceptance criteria that account for reasonable output variability, conduct repeated testing, evaluate challenging scenarios, and monitor performance. Where outputs influence critical GxP decisions, appropriate human review should also be established.

3. How can continuous learning be managed in AI systems?

Organizations should establish formal change control, maintain model version records, define revalidation triggers, and monitor performance after relevant changes. The approach should reflect whether the system learns during operation or receives periodic updates.

4. Why is data integrity important for AI validation in pharmaceutical companies?

AI systems rely on the quality and traceability of their data. Poor-quality or unreliable information can affect model performance and undermine confidence in its outputs. Appropriate data governance, access controls, audit trails, and provenance records help manage these risks.

5. How does GxP Cellators help address AI and CSV challenges?

GxP Cellators provides GxP auditing and compliance support that may include AI CSV strategy reviews, validation documentation reviews, model validation audits, data quality assessments, data integrity audits, and mock inspection support, depending on the agreed scope.

6. How can pharmaceutical companies prepare for AI-related regulatory inspections?

Companies should maintain clear documentation of intended use, risk assessments, validation testing, data governance, model changes, performance monitoring, and human oversight. They should also ensure that relevant personnel can explain the system’s role and limitations.

7. Where can I contact GxP Cellators for AI CSV validation support?

You can contact GxP Cellators through its official contact page to discuss your organization’s AI, CSV auditing, and GxP compliance requirements.

Conclusion

AI can offer significant benefits to pharmaceutical companies, but its integration into regulated computerized systems requires careful planning and ongoing oversight. Non-deterministic outputs, model changes, limited transparency, data quality issues, and evolving regulatory expectations can all affect validation activities.

By applying risk-based validation, maintaining reliable documentation, establishing appropriate change control, and monitoring system performance, organizations can better manage these challenges.

GxP Cellators can support relevant auditing and compliance review activities to help organizations identify potential gaps and strengthen their AI and CSV validation approach.

Need support with AI and CSV validation challenges? Visit the GxP Cellators to discuss your requirements.

by Vinod

12/10/2026

Artificial intelligence (AI) is becoming increasingly important in pharmaceutical manufacturing, laboratory operations, clinical research, and other regulated industries. Organizations use AI-based computerized systems to analyze data, support quality decisions, identify risks, and improve operational efficiency. However, when these systems support regulated activities, they must meet applicable Good Practice (GxP) requirements.

Validating AI-based computerized systems in a GxP environment requires a structured approach that goes beyond traditional Computerized System Validation (CSV). Unlike conventional software, some AI systems can produce results that depend on training data, model configuration, changing inputs, or model updates. Therefore, organizations must understand how these systems work, what risks they introduce, and how their performance can be monitored throughout their lifecycle.

This guide explains how to validate AI-based computerized systems in a GxP environment, covering intended use, training data, model development, human oversight, data integrity, and ongoing monitoring.

GxP Cellators provides GxP auditing, computerized system validation support, data integrity assessments, and regulatory compliance services to help organizations evaluate AI-related compliance risks and strengthen their validation processes.

What Is AI-Based Computerized System Validation in GxP?

AI-based computerized system validation is the documented process of establishing that an AI-enabled system is suitable for its intended use and performs reliably within its defined operating environment. The validation approach should be proportionate to the system’s intended use, complexity, and potential impact on product quality, patient safety, and data integrity.

Traditional CSV principles remain relevant, including documented requirements, risk assessment, testing, traceability, change control, and periodic review. However, AI systems may require additional controls because their outputs can be influenced by training data, model behavior, and changes in the operating environment.

For example, an AI tool used to support laboratory result review may affect decisions about data quality. Similarly, an AI application used in pharmaceutical manufacturing may help identify process deviations. If such systems support GxP activities, organizations should establish appropriate controls and document how their reliability and suitability have been evaluated.

AI validation does not automatically require the same testing approach for every system. Instead, the validation strategy should reflect the actual risks and intended use.

Step 1: Define Intended Use and Requirements

The first step is to clearly define the intended use of the AI-based computerized system. Organizations should document what the system is designed to do, which processes it supports, and how its outputs will be used.

A clear intended-use statement helps determine the scope of validation and the controls required throughout the system lifecycle.

Key activities include:

Documenting the intended use and purpose of the AI system.
Defining functional and non-functional requirements.
Identifying the GxP activities supported by the system.
Assessing potential impacts on product quality, patient safety, and data integrity.
Establishing measurable acceptance criteria.
Identifying system users, responsibilities, and access requirements.

A risk assessment should also determine the potential consequences of incorrect, incomplete, or unreliable AI outputs. For example, an AI system that provides recommendations for a quality decision may require different controls from one that performs a purely administrative task.

Requirements should be clear enough to support objective testing. Where an AI model produces probabilistic outputs, acceptance criteria should explain how its performance will be assessed and what limitations apply.

Step 2: Assess and Prepare Training Data

Training data plays a major role in AI system performance. Incomplete, inaccurate, unrepresentative, or biased data can affect model outputs and introduce compliance risks.

Therefore, organizations should evaluate the quality and suitability of training, validation, and test datasets as applicable to the AI model and its intended use.

Important activities include:

Documenting training data sources and ownership.
Assessing data completeness, accuracy, and representativeness.
Recording data cleaning and preprocessing activities.
Evaluating potential bias in the datasets.
Establishing controls for data access and protection.
Documenting known data limitations and their potential impact.
Maintaining traceability between datasets, model versions, and validation evidence.

Data preparation activities should be documented so that reviewers can understand how the data was selected, transformed, and used.

Organizations should also determine whether the data reflects the conditions in which the AI system will operate. A model trained using one type of process or dataset may not perform equally well under different conditions.

For GxP applications, training data quality assessments should be proportionate to the risk. Where data supports critical decisions, stronger evidence of data suitability, traceability, and integrity may be necessary.

Step 3: Document Model Development and Validation

AI model development should be sufficiently documented to support review, testing, and future maintenance. The level of detail will depend on the model type, system architecture, intended use, and regulatory risk.

Organizations should maintain records that explain how the model was developed and how its performance was evaluated.

Documentation should cover:

Model development methodology and architecture.
Key assumptions and known limitations.
Training, validation, and test data used.
Model configuration and version information.
Testing methods and performance metrics.
Validation results and acceptance criteria.
Identified risks and mitigation measures.
Approval records and supporting evidence.

Testing should evaluate whether the model performs as expected under defined conditions. Depending on the intended use, this may include accuracy, precision, sensitivity, specificity, robustness, reproducibility, or other appropriate performance measures.

Organizations should also consider how the model behaves with unusual, incomplete, or unexpected inputs. Testing only typical scenarios may not provide sufficient evidence of suitability for a regulated application.

Where applicable, the validation package should establish traceability between requirements, identified risks, test cases, results, and conclusions. This makes it easier to demonstrate why the system is considered suitable for its intended use.

Step 4: Establish Appropriate Human Oversight

Human oversight is an important control when AI outputs influence GxP decisions. Organizations should clearly define when human review is required, who is responsible for reviewing outputs, and what actions can be taken when the system produces questionable results.

Human oversight should be based on risk rather than treated as a general approval step.

Key activities include:

Defining human review and approval procedures.
Establishing override, rejection, and escalation processes.
Documenting significant human interventions.
Training personnel on the system’s capabilities and limitations.
Defining responsibilities for investigating unexpected outputs.
Maintaining records of decisions where required.

For example, if an AI system flags a potential quality issue, a qualified person may need to review the supporting evidence before taking further action. The review process should explain how disagreements between the AI output and human judgment are handled.

Training should help users understand that AI outputs may contain errors and should not automatically be accepted as correct. Personnel must also know when to escalate concerns and how to report unexpected system behavior.

The required level of oversight will depend on the system’s intended use, risk classification, and role in regulated decision-making.

Step 5: Implement Data Integrity and Security Controls

Data integrity is essential when AI-based computerized systems process or generate information used in GxP activities. Organizations should establish appropriate controls to protect records from unauthorized access, unintended changes, loss, or inappropriate deletion.

The controls should support applicable data integrity principles and relevant regulatory requirements.

Important measures include:

Implementing role-based access controls.
Maintaining appropriate audit trails for relevant records and activities.
Recording model versions and significant configuration changes.
Protecting input data, outputs, and associated metadata.
Establishing backup and recovery procedures.
Documenting data transfers and system interfaces.
Reviewing security risks and access permissions periodically.
Monitoring relevant data integrity issues.

Audit trails should provide suitable evidence of important activities, such as changes to records, model configurations, and system settings, where applicable. Organizations should also determine whether AI-generated outputs need to be retained and linked to the information used to produce them.

Data governance procedures should define responsibilities for managing datasets, model updates, access permissions, and records retention. These controls help maintain traceability and support investigations when unexpected results occur.

Step 6: Establish Ongoing Monitoring and Periodic Review

AI validation should not end when a system is initially approved. Depending on the technology, intended use, and risk, ongoing monitoring may be necessary to confirm that the system continues to perform as expected.

Changes in data, operating conditions, software components, or model versions can affect performance. Organizations should therefore establish a documented process for reviewing system performance throughout its lifecycle.

Ongoing monitoring activities may include:

Defining relevant performance indicators.
Establishing monitoring thresholds and review responsibilities.
Monitoring unexpected outputs and performance degradation.
Recording incidents, deviations, and investigations.
Evaluating proposed model or configuration changes.
Scheduling risk-based periodic reviews.
Updating validation documentation when necessary.
Establishing response and escalation plans.

Organizations should define what happens when a system fails to meet its established acceptance criteria. Depending on the impact, possible actions may include additional investigation, restricting system use, reverting to an approved configuration, or performing further testing before reapproval.

A formal change control process should determine whether changes require additional testing, regression testing, or partial or full revalidation. The decision should be documented and based on risk.

Common Challenges in AI-Based GxP Validation

Organizations may encounter several challenges when validating AI-enabled systems. Understanding these issues early can help establish a more effective validation strategy.

Limited Model Transparency

Some AI models are difficult to interpret. Organizations should document the available information about model behavior, limitations, and suitability for the intended use.

Inadequate Training Data

Poor-quality or unrepresentative datasets may lead to unreliable outputs. Data quality assessments and documented data governance procedures can help reduce this risk.

Changing Model Performance

AI systems may perform differently when operating conditions or input data change. Risk-based monitoring and defined escalation procedures help identify potential problems.

Insufficient Documentation

Missing records can make it difficult to demonstrate that the system has been adequately assessed. Requirements, testing evidence, model versions, approvals, and change records should be maintained appropriately.

Unclear Human Responsibilities

Without defined responsibilities, users may rely too heavily on AI-generated outputs. Organizations should document review requirements, decision authority, and escalation procedures.

Addressing these challenges during planning can help organizations build a stronger validation lifecycle and improve inspection readiness.

How GxP Cellators Supports AI-Based CSV Validation

GxP Cellators provides GxP auditing and compliance support to help pharmaceutical and other regulated organizations assess computerized systems and related quality processes.

Its support can help organizations identify documentation gaps, evaluate data integrity controls, review validation evidence, and assess whether established procedures address relevant compliance risks.

AI CSV Validation and Auditing Support

Services may include:

Validation strategy and documentation reviews.
AI model validation audits.
Training data quality assessments.
Data integrity audits.
Human oversight process reviews.
Regulatory compliance assessments.
Mock inspection support.
CAPA review and follow-up verification.
Risk assessment and gap identification.

Why Choose GxP Cellators?

GxP Cellators focuses on practical, risk-based compliance support for regulated environments.

Organizations can benefit from:

Experience across computerized system validation and GxP compliance.
Reviews informed by applicable FDA, EMA, Health Canada, MHRA, and WHO requirements and guidance.
Risk-based assessments tailored to the intended use of the system.
Actionable findings and recommendations.
Confidential handling of proprietary business and system information.

The precise validation requirements depend on the system, intended use, applicable regulations, and organizational quality procedures. GxP Cellators can help organizations assess their current approach and identify areas that may require improvement.

Best Practices for AI-Based Computerized System Validation

To strengthen the validation process, organizations should follow a structured and documented approach.

Start with intended use: Define the purpose and GxP impact before selecting validation activities.
Apply risk-based controls: Focus testing and oversight on risks to product quality, patient safety, and data integrity.
Maintain traceability: Link requirements, risks, test results, approvals, and relevant model versions.
Evaluate data quality: Document data sources, preparation methods, limitations, and suitability.
Define human responsibilities: Establish clear review, approval, override, and escalation procedures.
Control changes: Assess the impact of software, configuration, data, and model changes.
Monitor performance: Establish appropriate monitoring and periodic review procedures.
Prepare for inspection: Keep validation records organized, accessible, and consistent with approved procedures.

Following these practices can help organizations manage AI-related risks while maintaining an appropriate level of control over regulated computerized systems.

Frequently Asked Questions

Q1. What is the first step in validating an AI-based computerized system?

The first step is defining the intended use and requirements. Organizations should document what the AI system is designed to do, which GxP activities it supports, and the potential risks associated with its outputs.

Q2. How is training data validated for GxP AI systems?

Training data is assessed by documenting its sources, evaluating completeness and representativeness, reviewing preprocessing activities, and identifying potential bias. The assessment should also consider data integrity, traceability, and suitability for the intended use.

Q3. What human oversight is required for AI systems in GxP?

Human oversight may include defined review and approval procedures, override and rejection processes, escalation requirements, and documented interventions. The level of oversight should reflect the system’s intended use and risk.

Q4. How does AI-based CSV differ from traditional CSV?

Traditional CSV focuses on demonstrating that a computerized system meets its requirements and performs as intended. AI-based CSV retains these principles but may require additional assessment of training data, model performance, limitations, changing inputs, and ongoing monitoring.

Q5. Does an AI-based computerized system require revalidation after every update?

Not necessarily. Organizations should evaluate each proposed change through a documented change control and risk assessment process. Additional testing or revalidation should be determined by the potential impact of the change on the system’s validated state.

Q6. How does GxP Cellators support AI-based CSV validation?

GxP Cellators offers support such as validation documentation reviews, AI model validation audits, training data quality assessments, data integrity audits, regulatory compliance reviews, mock inspections, and CAPA follow-up verification.

Q7. Which regulatory requirements apply to AI-based GxP systems?

Requirements depend on the system’s intended use, industry, and applicable jurisdiction. Organizations should evaluate relevant regulatory requirements and guidance, including applicable FDA and EMA expectations, computerized system validation principles, and data integrity requirements.

Q8. How can I contact GxP Cellators for AI-based CSV validation support?

Visit the GxP Cellators contact page at https://www.gxpcellators.com/contact/ to discuss your computerized system validation, AI auditing, data integrity, or GxP compliance requirements.

Conclusion

Validating AI-based computerized systems in a GxP environment requires a documented, risk-based approach that considers intended use, data quality, model performance, human oversight, data integrity, and ongoing monitoring. Organizations should establish clear requirements, maintain appropriate validation evidence, and evaluate changes throughout the system lifecycle.

As AI adoption increases across regulated industries, effective validation and governance become increasingly important. A well-designed validation process can help organizations identify potential risks, improve system reliability, and support regulatory compliance.

GxP Cellators provides GxP auditing and compliance support to help organizations evaluate their validation practices and identify opportunities for improvement.

Contact GxP Cellators: https://www.gxpcellators.com/contact/

by Vinod

12/10/2026

This AI-based computerized system validation audit checklist provides a structured framework for auditing AI systems in GxP environments. It covers all key areas that auditors should examine and explains how GxP Cellators supports organizations through the audit process.

AI-Based CSV Audit Checklist

1. AI System Inventory and Risk Assessment

Have all AI applications been identified?
Is each application documented?
Has each application been risk assessed?
Is the risk assessment documented and approved?

2. AI Governance

Is there a documented governance framework?
Are roles and responsibilities defined?
Is there an oversight committee?
Are AI systems subject to change control?

3. Training Data

Is training data quality controlled?
Is training data representative?
Is there documentation of preprocessing?
Has training data been reviewed for bias?

4. Model Development

Is the development methodology documented?
Are requirements defined and traceable?
Has the model been validated?
Are performance metrics appropriate?

5. Model Documentation

Is the intended use documented?
Is the architecture documented?
Are limitations documented?
Is the version history documented?

6. Human Oversight

Is there a process for human review?
Are humans able to override the system?
Is there documentation of interventions?
Are personnel trained on AI limitations?

7. Data Integrity

Are audit trails enabled?
Are access controls in place?
Are outputs attributable?
Are model changes documented?

8. Security

Is the system protected from unauthorized access?
Is there protection against adversarial inputs?
Are security incidents documented?

9. Regulatory Compliance

Does the system comply with 21 CFR Part 11, where applicable?
Does the system comply with EU GMP Annex 11, where applicable?
Is the system compliant with applicable data integrity requirements?

10. Vendor Management

Has the vendor been qualified?
Is there a quality agreement?
Does the vendor provide validation documentation?
Is there a contingency plan?

How GxP Cellators Supports AI-Based CSV Audits

GxP Cellators provides comprehensive AI-based CSV audit services.

Our AI CSV Audit Services Include

Full-scope AI-based CSV audits
Pre-audit readiness assessments
AI governance framework reviews
Training data quality audits
AI model validation documentation reviews
Human oversight process audits
Data integrity audits
AI security assessments
Regulatory compliance reviews
Vendor and supplier audits
Mock AI audits
CAPA verification and follow-up

Why Choose GxP Cellators?

Auditors with deep experience in both CSV and AI technologies
Coverage of FDA, EMA, Health Canada, MHRA, and WHO requirements
A risk-based approach tailored to your systems
Practical, actionable reports
Full confidentiality for your proprietary systems

Frequently Asked Questions

Q1: What should be included in an AI-based CSV audit checklist?

An AI-based CSV audit checklist should cover AI system inventory, governance, training data, model development, model documentation, human oversight, data integrity, security, regulatory compliance, and vendor management.

Q2: How is AI-based CSV different from traditional CSV?

AI-based CSV must address non-determinism, continuous learning, opacity, and data dependency. Traditional CSV focuses on deterministic systems with defined requirements and testing.

Q3: What are common findings in AI-based CSV audits?

Common findings include incomplete AI system inventories, a lack of governance frameworks, inadequate training data documentation, insufficient model validation documentation, and inadequate human oversight.

Q4: How does GxP Cellators support AI-based CSV audits?

GxP Cellators provides full-scope AI-based CSV audits, pre-audit assessments, governance reviews, training data audits, model validation reviews, and mock inspections.

Q5: How do I contact GxP Cellators for AI-based CSV audit support?

You can reach us through our contact page to discuss your AI-based CSV audit requirements.

Contact GxP Cellators

If you need support with AI-based CSV audits, please contact GxP Cellators.

Contact: https://www.gxpcellators.com/contact/

by Vinod

09/10/2026

Computer System Validation has been a cornerstone of GxP compliance for decades. But AI-based systems are changing what validation means. This blog explains what has changed for validation with AI-based CSV audits and how GxP Cellators supports organizations through the transition.